TY - JOUR
T1 - Association between nonsteroidal anti-inflammatory drug use and major adverse cardiovascular events in patients with end-stage renal disease
T2 - a population-based cohort study
AU - Liao, Yu Chen
AU - Chang, Chuen Chau
AU - Chen, Ta Liang
AU - Liu, Chih Chung
AU - Chen, Hsi Hsien
AU - Lee, Yuan Wen
N1 - Funding Information:
This study was supported by a Grant from the Taiwan Ministry of Health and Welfare (CCMP102-RD-015). This study was based in part on data from the Taiwan National Health Insurance Research Database provided by the National Health Insurance Administration, Ministry of Health and Welfare and managed by National Health Research Institutes. The interpretations and conclusions contained herein do not represent those of the National Health Insurance Administration, Ministry of Health and Welfare or of the National Health Research Institutes. This manuscript was edited by Wallace Academic Editing.
Publisher Copyright:
© 2020, Italian Society of Nephrology.
Copyright:
Copyright 2020 Elsevier B.V., All rights reserved.
PY - 2021/4
Y1 - 2021/4
N2 - Background: Nonsteroidal anti-inflammatory drugs (NSAIDs) are commonly used for patients with end-stage renal disease (ESRD) despite clinical guideline recommendations that the use of NSAIDs be avoided in this population. However, the relationship between NSAID use and adverse cardiovascular events remains unclear. Thus, this study investigated the association between NSAID use and major adverse cardiovascular events (MACEs) in patients with ESRD. Methods: We used the Taiwan National Health Insurance Research Database to conduct this population-based cohort study of patients with newly diagnosed ESRD requiring long-term dialysis between 1998 and 2012. Clinical outcomes were evaluated until the end of 2013. Time-dependent Cox regression models were used to investigate the association between NSAID use and MACEs in patients with ESRD. Results: Among 2349 patients with ESRD receiving dialysis, 1923 (82%) patients used NSAIDs during the follow-up period. Multivariable analysis revealed that compared with nonusers, NSAID users exhibited an increased risk of MACEs with an adjusted hazard ratio (HR) of 1.70 (95% confidence interval [CI] 1.22–2.36). Further analysis demonstrated a significant dose–response relationship between the cumulative use of NSAIDs and MACEs. Adjusted HRs for MACEs were 1.63 (95% CI 1.16–2.30), 1.86 (95% CI 1.22–2.83), and 1.99 (95% CI 1.24–3.20) for cumulative NSAID use of 1–30 defined daily doses (DDDs), 31–90 DDDs, and > 90 DDDs, respectively. Conclusions: The results of this study suggest that NSAID use may increase the risk of MACEs in patients with ESRD. Clinicians and patients with ESRD should be aware of the potential cardiovascular risks associated with NSAIDs.
AB - Background: Nonsteroidal anti-inflammatory drugs (NSAIDs) are commonly used for patients with end-stage renal disease (ESRD) despite clinical guideline recommendations that the use of NSAIDs be avoided in this population. However, the relationship between NSAID use and adverse cardiovascular events remains unclear. Thus, this study investigated the association between NSAID use and major adverse cardiovascular events (MACEs) in patients with ESRD. Methods: We used the Taiwan National Health Insurance Research Database to conduct this population-based cohort study of patients with newly diagnosed ESRD requiring long-term dialysis between 1998 and 2012. Clinical outcomes were evaluated until the end of 2013. Time-dependent Cox regression models were used to investigate the association between NSAID use and MACEs in patients with ESRD. Results: Among 2349 patients with ESRD receiving dialysis, 1923 (82%) patients used NSAIDs during the follow-up period. Multivariable analysis revealed that compared with nonusers, NSAID users exhibited an increased risk of MACEs with an adjusted hazard ratio (HR) of 1.70 (95% confidence interval [CI] 1.22–2.36). Further analysis demonstrated a significant dose–response relationship between the cumulative use of NSAIDs and MACEs. Adjusted HRs for MACEs were 1.63 (95% CI 1.16–2.30), 1.86 (95% CI 1.22–2.83), and 1.99 (95% CI 1.24–3.20) for cumulative NSAID use of 1–30 defined daily doses (DDDs), 31–90 DDDs, and > 90 DDDs, respectively. Conclusions: The results of this study suggest that NSAID use may increase the risk of MACEs in patients with ESRD. Clinicians and patients with ESRD should be aware of the potential cardiovascular risks associated with NSAIDs.
KW - End-stage renal disease
KW - Major adverse cardiovascular events
KW - Nonsteroidal anti-inflammatory drugs
KW - Pain
UR - http://www.scopus.com/inward/record.url?scp=85089866458&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85089866458&partnerID=8YFLogxK
U2 - 10.1007/s40620-020-00830-0
DO - 10.1007/s40620-020-00830-0
M3 - Article
AN - SCOPUS:85089866458
SN - 1121-8428
VL - 34
SP - 441
EP - 449
JO - Journal of Nephrology
JF - Journal of Nephrology
IS - 2
ER -